Diabetes Mellitus, Type 2

35 competing products in clinical development for Diabetes Mellitus, Type 2.

Pipeline by Phase

Pre-clinical3

Phase 16

Phase 26

Phase 2/31

Phase 313

Approved6

All Products (35)

Product	Company	Stage	Status	Hype
Retatrutide + Semaglutide	Eli Lilly	Phase 3	Active	44
Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)	Eli Lilly	Approved	Completed	43
Lispro	Eli Lilly	Approved	Completed	43
premeal insulin lispro mixtures + insulin glargine + metformin	Eli Lilly	Approved	Completed	43
Pioglitazone + Alogliptin + Alogliptin + Metformin + Dapagliflozin	Celltrion	Approved	Completed	43
Insulin Lispro-aabc + Insulin Glargine	Cipla	Approved	Completed	43
AC2993	Eli Lilly	Phase 3	Completed	40
Insulin Lispro Protamine Suspension + Insulin Glargine	Eli Lilly	Phase 3	Completed	40
Placebo + Linagliptin	Eli Lilly	Phase 3	Completed	40
Linagliptin + Empagliflozin placebo + linagliptin placebo low dose + Empagliflozin + linagliptin low dose + Linagliptin placebo + Empagliflozin + linagliptin high dose + Empa + lina highdose placebo	Eli Lilly	Phase 3	Completed	40
Placebo + BI 10773 + Placebo + BI 10773 + Placebo + Placebo	Eli Lilly	Phase 3	Completed	40
placebo + linagliptin + background therapy	Eli Lilly	Phase 3	Completed	40
LY2189265 + Exenatide + Placebo + Metformin + Pioglitazone	Eli Lilly	Phase 3	Completed	40
Olmesartan medoxomil + Placebo Tablets	Daiichi Sankyo	Phase 3	Completed	40
Human Insulin Inhalation Powder + Neutral protamine hagedorn insulin	Eli Lilly	Phase 2/3	Completed	38
Tirzepatide	Eli Lilly	Phase 1	Recruiting	36
LY2428757 + Placebo	Eli Lilly	Phase 2	Completed	35
CS-917 + metformin hydrochloride + pioglitazone	Daiichi Sankyo	Phase 2	Completed	35
ipragliflozin + Metformin + Placebo	Astellas Pharma	Phase 2	Completed	35
YM543 + Metformin + Placebo	Astellas Pharma	Phase 2	Completed	35
ASP1941 + Placebo	Astellas Pharma	Phase 2	Completed	35
ONO-5129	Ono Pharmaceutical	Phase 2	Completed	35
Toujeo	MIRA Pharmaceuticals	Approved	Completed	33
Empagliflozin + Placebo + Sitagliptin + Placebo	Eli Lilly	Phase 3	Withdrawn	32
Empagliflozin + DPP-4 inhibitor + GLP-1 receptor agonist	Eli Lilly	Pre-clinical	Active	30
Humalog Mix25 + Insulin Lispro Biphasic 25	GEROPHARM	Phase 3	Completed	30
Insulin Humulin® NPH + Insulin Rinsulin® NPH	GEROPHARM	Phase 3	Completed	30
LY3209590 + Insulin Degludec	Eli Lilly	Phase 1	Completed	29
LY3209590 + Placebo	Eli Lilly	Phase 1	Completed	29
LY900014 (SC) + LY900014 (IV)	Eli Lilly	Phase 1	Completed	29
Placebo + LY2922470	Eli Lilly	Phase 1	Completed	29
Placebo + LY2922083	Eli Lilly	Phase 1	Completed	29
empagliflozin + DPP-4 inhibitors	Eli Lilly	Pre-clinical	Completed	26
GP40081 + NovoMix 30	GEROPHARM	Phase 3	UNKNOWN	26
Ipragliflozin (SGLT2 inhibitor)	Astellas Pharma	Pre-clinical	Completed	26